Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, Diogenes of Sinope, AMG, euroconversions , UCParadise, hoyowasobo
Search This Board: 
Last Post: 3/21/2018 10:36:03 PM - Followers: 95 - Board type: Free - Posts Today: 0


September 5th 2017 

Issued and outstanding common shares 54,752,024 

Warrants outstanding 26,029,676 

Stock options outstanding. 3,495,000

Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.

Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry.

The principal market opportunity arises from the potential of low-cost, non-intrusive diagnostic screening in general medical practice which could lead to notable advances in early detection of major cancers and other life-altering diseases.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life


High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)

Function: Compounds (Ions) are Separated by Mobility

  • Function of the size, shape, charge
    Direct, real-time separation
    Continuous sample introduction

An Ion filter – only molecules of interest are allowed to be detected

FAIMS Technical Overview

Breathtec Biomedical aims to assist the development of novel instrumentation and methodologies for high-field asymmetric waveform ion mobility spectrometry(FAIMS). FAIMS can be performed on a standalone device, or, more prominently, coupled to a mass spectrometer (MS). FAIMS is a separation technique which allows continuous sample introduction, enabling direct, real-time analysis.

FAIMS (or differential mobility spectrometry, DMS) involves separation based on the inherent differences in an ion’s mobility in high and low electric fields, and can be performed at atmospheric pressure and room temperature

Corporate Presentation

Company filings


Chief Executive Officer



Alfred Wong

Vice President, Corporate Development & Communications
2017 - Current 
Breathtec Biomedical, Inc. engages in the provision of medical diagnostic and health-related technology. It involves in the development of commercially viable methods such as of breath analysis screening technologies for the early screening of diseases such as lung, breast cancers, neurodegenerative diseases, tuberculosis, diabetes, liver diseases, and others. The company was founded on January 22, 2015 and is headquartered in Vancouver. Canada.



Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.



Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.



Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2 


Breathtec Biomedical Provides Corporate Overview


-- Company offers update of events and outlook for near term opportunity


VANCOUVER, BRITISH COLUMBIA – October 17, 2016 – Breathtec BioMedical, Inc(CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.


In response to recent volatility in its share price, the Company notesthat fluctuations are an example of development stage market volatility which in Management’s opinion should be viewed in the context of the Company’s underlying financial health and strength of its product portfolio. Breathtec maintains a healthy working capital position of $1.3M. Additionally, management of the Company have voluntarily escrowed a significant number of shares with no insider sales having occurred or contemplatedw.


Breathtec’s technology portfolio continues to move ahead with all licensing and development agreements in-place and a number of ongoing achievements and development phases underway. A brief summary of recent and ongoing activities is summarized below. 


FAIMS Technology:

Breathtec continues to progress its flagship FAIMS technology with the recent completion of a V2 prototype breathalyzer design. The latest design has significant advances over the previous prototype including larger dynamic range and improved efficiency in the square waveform generator, greater sensitivity achievable by the detector, improvements in the design, implementation of the novel ionization source, and is overall more than 10X smaller than the V1 prototype.The current design is well under development and includes features to allow for the addition of an onboard processor, touch screen and rechargeable battery in a handheld device configuration.



Regulatory Pathway:

Management has engaged regulatory consultants with extensiveexperience in medical device and in vitro diagnostics strategies to evaluate potential regulatory options to propel the FAIMS technology platforms to market. The Company has furtherengaged experienced product development consultants to initiate the design controls, and quality systems processes to meet regulatory approval and to lead the establishment of product manufacturing protocols as a precursor to commercialization.


Professional Collaboration:

Dr. Michael Costanzo, Breathtec’s CTO recently gave a well-received presentation Developing a Point-of-Care Device for Breath Analysis Utilizing FAIMS and FAIMS/MS,” to a prestigious group of leading experts in the field of breath analysis in Zurich, Switzerland. At the event, Dr. Costanzo affirmedBreathtec anticipates completion of a prototype of the FAIMS device in Q4 of 2016 and will work alongside our partner to advance the technology towards the clinic.” Dr. Costanzo’s presentation can be found here:


Company CEO at the time, Guy LaTorre comments, “We earnestly appreciate the continued interest and support of all our stakeholders, partners, affiliates and shareholders alike. As such, I wanted to take this opportunity to recap our continued technical achievements as we continue to be motivated daily with overwhelmingly positive feedback as regards the need for a Point-of-Care device such as ours as a means to save countless healthcare dollars and untold numbers of lives in the foreseeable future. These factors compel us to move ahead as quickly as possible with this exciting endeavor and we sincerely thank our supporters for the means to do so.”





For further information, please contact:
Alfred Wong

President & Director

Breathtec BioMedical, Inc





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTHCF News: Breathtec Biomedical Provides Development Update on Breathalyzer for Disease Detection 01/25/2018 07:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3227  Sticky Note Breathtec Biomedical Announces Appointment of CEO shell3 03/01/18 09:17:30 AM
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#3323   Follow Up: Keeping in mind, Dr. Richard Yost AMG 03/21/18 10:36:03 PM
#3322   Yes... we found the Right person(s) Yost Research smoki 03/21/18 10:21:29 PM
#3321   What the article tells me is Nash Pharma AMG 03/21/18 09:56:24 PM
#3320 smoki 03/21/18 09:11:56 PM
#3319   was supposed to say "test" RJacques 03/20/18 01:54:33 PM
#3318   teat since last post 3/14 RJacques 03/20/18 01:41:56 PM
#3316   Don't hold your "Breath" on it. He's a drifter. RJacques 03/14/18 06:16:22 PM
#3315   Need to hear something from our New MM3rd 03/14/18 10:58:14 AM
#3314   Deal ... smoki 03/10/18 01:04:49 AM
#3313   Save the post # 3309 ......when it's 10.00 smoki 03/09/18 01:52:43 PM
#3312   Yes, a shell game artist per my prior posts. RJacques 03/09/18 01:33:17 PM
#3311   Money Talks .... made lots here and over smoki 03/09/18 12:59:40 PM
#3310   I'm betting folks can say the same for AMG 03/09/18 12:55:47 PM
#3309   BIGGER than Sister !!! Cheapies here, honest!! smoki 03/09/18 12:54:29 PM
#3308   Give it a rest already AMG ..... smoki 03/09/18 12:52:38 PM
#3307   My concern is whether or not he's a AMG 03/09/18 12:49:23 PM
#3305   STAY TUNED.....;$ smoki 03/09/18 12:11:15 PM
#3304   How long does a new CEO need to iluv blozf 03/09/18 12:08:01 PM
#3303   JMO......think the New's will be non - stop smoki 03/09/18 10:25:59 AM
#3302   The future of Breathtec is a puzzling prospect AMG 03/08/18 08:27:47 PM
#3301   Jmo... last run down here ... rocket smoki 03/08/18 01:15:31 PM
#3300   Gathering some more of Sister's Lucky Charms ;)) smoki 03/08/18 12:35:24 PM
#3299   Shell if I'm understanding you correctly, are you AMG 03/08/18 09:14:36 AM
#3298   I hope that’s not the game plan here shell3 03/08/18 08:57:14 AM
#3297   As in Nash Pharma (another non revenue, soul AMG 03/08/18 08:46:53 AM
#3296   Christopher’s hands-on and results-driven approach will help Breathtec’s shell3 03/08/18 03:36:58 AM
#3295   About the Nash guy ... our new CEO smoki 03/07/18 08:33:51 PM
#3294   Update on Sedar... Nash smoki 03/07/18 05:57:49 PM
#3293   Not "pleased". RJacques 03/05/18 06:11:05 PM
#3292   He delivers a line of b.. Miraculins RJacques 03/05/18 06:07:40 PM
#3291   Grabbed from NASH website shell3 03/05/18 03:21:31 PM
#3290   Rotten fishy RJacques 03/05/18 03:17:37 PM
#3289   This quote is medical scientific nonsense and undermines RJacques 03/05/18 03:14:31 PM
#3288   My immediate family member has it ... god's speed smoki 03/05/18 01:51:30 AM
#3287   We also ran to .41 BTHCF with no NEWS shell3 03/04/18 09:04:53 PM
#3286   If V3 could not get the stock price AMG 03/04/18 08:50:01 PM
#3285   Yeah I haven’t a clue who he is shell3 03/04/18 08:13:57 PM
#3284   Shell...well into that "90M" CAD inked deal...Miraculins appeared AMG 03/04/18 07:57:35 PM
#3283   OLD VIDEO of BreathTec NEW CEO shell3 03/04/18 07:15:46 PM
#3282   Christopher J. Moreau shell3 03/04/18 06:59:52 PM
#3281   Breathtec Biomedical Inc. (CSE:BTH) (CNSX:BTH) (FRANKFURT:BTI) (OTCQB:BTHCF) (th shell3 03/04/18 06:53:46 PM
#3280   Mr. Christopher J. Moreau has been the Chief shell3 03/04/18 06:51:46 PM
#3279   A quote from NASH Pharmaceuticals shell3 03/04/18 06:48:26 PM
#3276   ...... having to agree with that now after smoki 03/04/18 12:08:26 PM
#3275   96.34% of Vol Shorted Mar 02 shell3 03/04/18 11:51:31 AM
#3274   March 2, 2018 Outstanding : 57,297,357 shell3 03/04/18 08:10:04 AM
#3273   FORM 7 - MONTHLY PROGRESS REPORT shell3 03/04/18 08:07:08 AM
#3272   5th report due Monday ......Nash one of the smoki 03/03/18 10:45:10 PM
#3271's not about me. Just pay attention to AMG 03/03/18 05:38:48 PM
#3270   You won't win.... smoki 03/03/18 05:36:07 PM